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Non-small cell lung cancerEZH2 is a key component of the polycomb PRC2 complex and functions as a histone H3 Lys27
(H3K27) trimethyltransferase. Here we show that EZH2 is down-regulated in human non-small cell
lung cancer and low EZH2 expression predicts poor survival. Further we demonstrate that EZH2
inhibits lung cancer cell proliferation and colony formation in vitro and growth in vivo. We found
that EZH2 binds to the promoter of Nrf2, where it increases H3K27me3 and represses Nrf2 expres-
sion. Finally, Nrf2 seems to be essential for the hyper proliferation of lung cancer cells in the absence
of EZH2.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Post-translational modiﬁcation of histones by methylation is an
important and widespread type of chromatin modiﬁcation that is
known to inﬂuence biological processes in the context of
development and cellular responses [1]. Histone lysine methyla-
tion is a critical player in the regulation of gene expression, cell
cycle, genome stability, and nuclear architecture [2]. Lysines can
be monomethylated (me1), dimethylated (me2) or trimethylated
(me3) on their e-amine groups [1]. The most extensively studied
histone methylation sites include histone H3 lysine 4 (H3K4),
H3K9, H3K27, H3K36, H3K79 and H4K20 [1]. Trimethylation of his-
tone H3 lysine 27 (H3K27me3), catalyzed by the PcG enhancer of
zester homolog 2 (EZH2), is associated with transcriptional
repression; whereas H3K4 methylation, catalyzed by the trithorax
homolog myeloid-lymphoid leukemia (MLL), is associated with
transcriptional activation [3]. Importantly, many genes involved
in development, stem cell maintenance, and differentiation are tar-
gets of H3K27 and H3K4 methylation. Alteration of histone methylmodiﬁers and methyl-binding proteins correlates with increased
incidence of various cancers [4,5]. One typical example is the
H3K27 methyltransferase EZH2. EZH2 is up-regulated in a number
of cancers, including prostate cancer [6], breast cancer [7], and
lymphomas [8].
Lung cancer is one of the leading causes of cancer-related death
in developed countries. Despite decades of intensive efforts, the
prognosis of lung cancer remains unfavorable and is especially
poor in advanced non-small cell lung cancer (NSCLC). One of the
main causes of the poor outcome in NSCLC treatment is the innate
resistance to anticancer drugs. The transcription factor NF-E2-
related factor 2 (Nrf2) is a basic-leucine-zipper transcription factor
originally identiﬁed as a pivotal factor for protecting cells from oxi-
dative and electrophilic insults [9]. Nrf2 effector genes include a
majority of anti-oxidative, phase II detoxifying enzymes, and
ATP-dependent drug efﬂux pumps [10,11]. Activation of Nrf2 in
cancer cells provides advantages for cell proliferation and survival
from exposure to anticancer drugs [12,13]. Several studies have
implicated the role of Nrf2 in tumor growth and drug-resistance
in NSCLC [11,14–17]. Our recent work showed that hMOF acety-
lates Nrf2 and promotes its nucleus retention in human NSCLC
[18]. However, how Nrf2 is controlled at the transcription level
remains unknown.
Here in this study, we report that EZH2 represses NSCLC pro-
gress by epigenetically inhibiting Nrf2 expression.
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2.1. Patients
54 patients with NSCLC were included in this study. The
patients were recruited at Shanghai Lung Tumor Clinical Medical
Center, Shanghai Chest Hospital, Shanghai Jiao Tong University.
The 11 adjacent normal lung tissues were obtained from NSCLC
patients undergoing surgery. The clinical characteristics of the
patients is listed in Table 1. The diagnosis of lung cancer was
established using World Health Organization (WHO) morpholog-
ical criteria. Both the adjacent normal tissues and the lung can-
cer tissues were conﬁrmed by a pathologist. Clinicopathological
parameters including age, gender, smoking history, histologic
grade, tumor status, lymph node metastasis and histologic
type were analyzed. A written form of informed consent was
obtained from all patients, and the study was approved by the
Clinical Research Ethics Committee of Shanghai Jiaotong
University.
2.2. Cells and cell culture
Human lung cancer cell line A549 was obtained from Riken Bio-
Resource. The cells were cultured in high glucose-containing
DMEM supplemented with 10% FBS, 100 units/ml penicillin and
100 lg/ml streptomycin.
2.3. Quantitative real-time PCR (q-PCR)
Total RNA samples were extracted from tissues or cells with
TRIzol regent (TaKaRa). cDNA was synthesized from 2 lg of RNA
with One Step RT-PCR Kit (TaKaRa). q-PCR was performed with
the SYBR Green (TaKaRa) detection method on an ABI-7500 RT-
PCR system (Applied Biosystems). The EZH2 primers
(NM_004456), Nrf2 primers (NM_006164), NQO-1 primers
(NM_000903), and HO-1 primers (NM_002133) were purchased
from OriGene Technology.Table 1
Clinical characteristics of the patients with NSCLC.







P60 32 17 15 0.418
<60 22 9 13
Gender
Male 34 15 19 0.4396
Female 20 11 9
Smoking history
Never 19 7 12 0.0205
Ever 35 25 10
Histology type





P3 30 20 10 0.003
<3 24 6 18
Metastasis and recurrence
Present 21 15 6 0.0113
Absent 33 11 22
Stage
I 8 1 10 0.0056
II 17 6 8
III 29 19 102.4. Western blot
Tissues and lung cancer cells were lysed with cell lysis buffer
(Beyotime) supplemented with protease inhibitor cocktail. 40 lg
total proteins were applied to 12% SDS–polyacrylamide gel. After
electrophoresis, the proteins were transferred to PVDF membranes,
followed by blocking in the buffer containing 5% fat-free dry milk.
The membranes were then probed with indicated antibodies
overnight, and then washed and incubated with HRP-conjugated
secondary antibodies (Zhongsanjinqiao) for 2 h and ﬁnally
visualized using Chemiluminescent ECL reagent (Vigorous Biotech-
nology). The following antibodies were used: Anti-GAPDH (Cell
Signaling Technology, #2118), anti-EZH2 (Cell Signaling Technol-
ogy, #4905), anti-Nrf2 (Abcam, #ab31163), anti-H3K27me3
(Abcam, #ab6002), anti-Histone H3 (Abcam, #ab1791).
2.5. Adenovirus/retrovirus packaging and retroviral transduction
To prepare EZH2-expressing adenovirus, the human EZH2 cDNA
was inserted into D-TOPO vector (Invitrogen). The D-TOPO-EZH2
plasmid was cloned into the pAd/CMV/V5-DEST vector (Invitrogen)
using LR Clonase (Invitrogen). The plasmid was linearized with
PacI and was transfected into 293A cells for production of adenovi-
rus. For Ad-Ctrl, the GFP cDNA was inserted into D-TOPO vector
instead of EZH2 cDNA. Control shRNA and speciﬁc shRNAs target-
ing EZH2 or Nrf2 were purchased from Invitrogen, and the corre-
sponding sequences were cloned into the pSIREN-RetroQ plasmid
(Addgene) for retrovirus production with 293T cells. The targeting
sequences were listed in Supplementary Table 1.
For transduction, 293T cells were incubated with virus-contain-
ing supernatant in the presence of 8 mg/ml polybrene. After 48 h,
infected cells were selected for with puromycin (2 mg/ml). Then
the clones were picked and cultured for further experiment.
2.6. Chromatin immunoprecipitation (ChIP)
ChIP was carried out using the ChIP-IT Express Enzymatic kit
(Active Motif) according to the manufacturer’s instructions. In
brief, chromatin from cells was cross-linked with 1% formaldehyde
(10 min at 22 C), sheared to an average size of 500 bp and then
immunoprecipitated with anti-EZH2, anti-IgG or anti-H3K27me3
antibodies. q-PCR was performed to the test the binding ability
of EZH2 to Nrf2 promoter regions. The detailed information on
EZH2 binding regions and the primers were given in Supplemen-
tary Fig. 1 and Table 2.
2.7. Cell proliferation assay
Cell proliferation was monitored by a 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) Cell Proliferation/Via-
bility Assay kit (R&D SYSTEMS) in according to the guidelines.
2.8. Soft sugar colony formation assay
Soft sugar colony formation assay was performed as described
previously [19]. Cell colonies were stained with 0.005% crystal
violet and analyzed using a microscope. The colony number in each
well was calculated.
2.9. Luciferase assay
We designed the luciferase assay in according to the results of
ChIP assay, and the region where EZH2 binds most frequently
was chose for luciferase assay. In detail, the human Nrf2 (750
to 0 bp) promoter was cloned into the pGL4 reporter vector
(Promega) to generate an Nrf2-luc reporter vector. 293T cells were
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ence. The cells were then co-transfected with Nrf2-Luc/p-RL-luc
and EZH2 expressing or control vectors as indicated in the ﬁgure
legend. Dual luciferase assays (Promega) were performed as
described by the manufacturer.
2.10. Xenograft mice experiment
Xenograft mice experiments were performed as described
previously [20]. In brief, equal numbers of A549 cells expressing
either control or EZH2 knockdown/overexpression vectors were
injected subcutaneously, within 30 min of harvesting, over the
right and left ﬂanks in male nu/nu mice between 4 and 6 weeks
of age. Tumor growth was monitored using calipers. The mice were
killed and the tumors were weighted 3 weeks after inoculation.
N = 10 in each group.
2.11. Statistical analysis
All values are expressed as the means ± S.E.M. At least three
replicates were applied for each experiments if no additional
information was indicated in this study. Statistical differences
among groups were determined using either Student’s t test or
one-way ANOVA. The correlation of EZH2 mRNA level with
patients’ clinicopathological variables was analyzed by the v2 test
or Fisher’s exact test. P values of less than 0.05 were considered
statistically signiﬁcant.
3. Results
3.1. EZH2 is decreased in NSCLC and low EZH2 level predicts poor
survival
To investigate EZH2 function in human NSCLC, we examined
changes in EZH2 mRNA and protein expression in human NSCLCFig. 1. EZH2 expression decreases in NSCLC and low EZH2 level predicts poor survival. (
determined with q-PCR in adjacent normal lung tissues versus lung cancer tissues. The b
range; bars represent the median. N = 11 in normal group; n = 54 in NSCLC group. (B) EZ
adjacent normal lung tissues and lung cancer tissues from different stages, and the prote
tissues; I: Stage I; II: Stage II; III: Stage III. (C, D) Kaplan–Meier curve comparing tim
percentile) EZH2 expression was determined using the q-PCR results. (C) Overall survivand adjacent normal tissues. The results showed that EZH2
expression was signiﬁcantly down-regulated in NSCLC tissues at
mRNA and protein levels (Fig. 1A and B), and EZH2 level decreased
with the development of cancer (Fig. 1B). Those data implicates
that EZH2 may participate in the development and prognosis of
NSCLC. To test this hypothesis, we analyzed the correlation
between mRNA level of EZH2 and overall and disease-free survival
in patients with NSCLC. Markedly, low expression of EZH2was cor-
related with poor overall and disease-free survival (Fig. 1C and D).
In addition, low EZH2 level was correlated with large tumor size,
high metastasis, and high disease stage (Table 1). Those results
indicate that EZH2 expression is down-regulated in human NSCLC
tissues and that low level of EZH2 predicts poor survival.
3.2. EZH2 regulates lung cancer cell growth in vitro and in vivo
To explore the role of EZH2 in lung cancer cell growth, we per-
formed cellular proliferation and colony formation experiments
in vitro and xenograft mice experiments in vivo. We knocked down
EZH2 expression in A549 lung cancer cells and found that EZH2
knockdown promoted A549 cell proliferation (Fig. 2A, Supplemen-
tary Fig. 1A and B). In contrast, when EZH2 was overexpressed, the
proliferation rate of A549 cells decreased signiﬁcantly (Fig. 2B).
Next, we evaluated the colony formation capacity. The results
showed that EZH2 knockdown up-regulated colony formation
activity of A549 cells (Fig. 2C, Supplementary Fig. 1C, D and 2A),
while EZH2 overexpression reduced colony formation activity of
A549 cells (Fig. 2D, Supplementary Fig. 2B). Those results indicate
that EZH2 inhibits lung cancer growth in vitro, which prompted us
to conﬁrm the role of EZH2 in lung cancer in vivo. Therefore, we
performed xenograft mice experiments. Our results showed that
EZH2 knockdown increased the average tumor weight (Fig. 2E,
Supplementary Fig. 3A), whereas EZH2 overexpression decreased
the average tumor weight of lung cancer (Fig. 2F, Supplementary
Fig. 3B). Taken together, our ﬁndings demonstrate that EZH2 inhib-
its lung cancer growth in vitro and in vivo.A) EZH2 mRNA level is decreased in human NSCLC tissues. EZH2 mRNA levels were
oxes represent the interquartile range; whiskers represent the 10th–90th percentile
H2 protein level is decreased in human NSCLC tissues. Protein was extracted from
in was subjected to Western blot analysis with indicated antibodies. N: Normal lung
e to survival between NSCLCs with the low (<25th percentile) versus high (>25th
al. (D) Disease-free survival.
Fig. 2. EZH2 expression regulates lung cancer growth in vitro and in vivo. (A) EZH2 knockdown promotes A549 lung cancer cell proliferation. A549 lung cancer cells were
infected with retrovirus expressing ctrl shRNA (sh-Ctrl) or shRNA targeting EZH2 (sh-EZH2-1#). The relative cell numbers were evaluated with MTT method at the indicated
time points. (B) EZH2 overexpression inhibits A549 lung cancer cell proliferation. A549 lung cancer cells were infected with adenovirus expressing GFP (Ad-Ctrl) or EZH2 (Ad-
EZH2). The relative cell numbers were evaluated at the indicated time points. (C) EZH2 knockdown promotes A549 lung cancer cell colony formation. A549 cells infected with
retro-sh-Ctrl or retro-sh-EZH2-1# were subjected to soft sugar colony formation assay. The colony numbers were evaluated two weeks later. (D) EZH2 overexpression
inhibits A549 lung cancer cell colony formation. A549 cells infected with Ad-Ctrl or Ad-EZH2 were subjected to soft sugar colony formation assay. The colony numbers were
evaluated two weeks later. (E, F) A549 cells with EZH2 knockdown or overexpression were subjected to xenograft mice experiments. Tumor weight was evaluated at the end
of the experiments. (E) EZH2 knockdown facilitates lung cancer cell growth in vivo. (F) EZH2 overexpression inhibits lung cancer cell growth in vivo. ⁄P < 0.05; ⁄⁄P < 0.01.
Fig. 3. EZH2 is correlated with the expression of Nrf2 and its downstream genes. (A–C) Nrf2, NQO-1 and HO-1 mRNA levels were determined in adjacent normal lung tissues
versus lung cancer tissues. The boxes represent the interquartile range; whiskers represent the 10th–90th percentile range; bars represent the median. (A) Nrf2 mRNA is
increased in lung cancer tissues. (B) NQO-1 mRNA level is increased in lung cancer tissues. (C) HO-1 mRNA level is increased in lung cancer tissues. N = 11 in normal group;
n = 44 in NSCLC group. (D–F) Linear regression analysis was performed to analyze the correlation between EZH2 expression and Nrf2, NQO-1 or HO-1 expression. (D) EZH2
mRNA level is negatively correlated with the level of Nrf2. (E) EZH2 mRNA level is negatively correlated with the level of NQO-1. (F) EZH2 mRNA level is negatively correlated
with the level of HO-1.
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As we have showed that EZH2 controlled lung cancer growth
and predicted patients’ survival. We next wanted to know theunderling mechanism by which EZH2 regulates lung cancer
growth. Nrf2 is a transcription factor that was reported to regulate
lung cancer proliferation and drug-resistance [11,15,21,22].
Accumulating data have shown the high expression of Nrf2 in
3004 Z. Li et al. / FEBS Letters 588 (2014) 3000–3007the tissues of human NSCLC as described in the introduction.
However, how Nrf2 is regulated at the transcription level remains
elusive. A previous report showed that when cancer cells were
treated with proteasome inhibitor MG132, EZH2 was down-
regulated, which was coupled with the up-regulation of Nrf1 and
Nrf2 [23]. Therefore, we hypothesized that EZH2 may regulate
Nrf2 expression in lung cancer cells. First, we explored the expres-
sion level of Nrf2 and its downstream genes (NQO-1 and HO-1) in
lung cancer tissues and adjacent normal tissues. We found that
Nrf2 was overexpressed in human NSCLC tissues (Figs. 3A and
4D). In addition, NQO-1 and HO-1, two genes transcriptionally con-
trolled by Nrf2 and participate signiﬁcantly in NSCLC growth and
drug-resistance, were also up-regulated in NSCLC tissues (Fig. 3B
and C). Next, we performed linear regression analysis to analyze
the correlation between EZH2 mRNA level and Nrf2, NQO-1 and
HO-1 mRNA levels. The results showed that EZH2 mRNA level
was negatively but signiﬁcantly correlated with the mRNA levels
of Nrf2, NQO-1 and HO-1 (Fig. 3D–F). Interestingly, we found that
EZH2 can bind to the promoter region of Nrf2 gene in lung cancer
tissues and cell lines (Fig. 4A, Supplementary Fig. 4), but not to the
promoter region of NQO-1 or HO-1 gene (Supplementary Fig. 5). As
EZH2 is an H3K27me3 methyltransferase, we also investigated the
enrichment of H3K27me3 at the promoter region of Nrf2 gene. The
results showed that the H3K27 at Nrf2 promoter was trimethylated
(Fig. 4B). Interestingly, EZH2 level and the methylation level of
H3K27me3 at Nrf2 promoter was signiﬁcantly down-regulated in
NSCLC tissues compared with adjacent normal tissues (Fig. 4C).
In addition, we also found the global decrease in H3K27me3 level
in NSCLC tissues compared to adjacent normal tissues (Fig. 4D).
Because H3K27me3 is correlated with transcription regression,
we wanted to know whether low methylation of H3K27me3
enrichment at Nrf2 promoter is correlated with high Nrf2
expression. Our linear regression analysis indicated that
H3K27me3 enrichment at Nrf2 promoter was negatively butFig. 4. H3K27me3 is involved in EZH2 effects on Nrf2 expression. (A, B) NSCLC tissues w
antibodies. The values were expressed as percentage of input. HoxA10 serves as positive
Nrf2 gene. N = 5 in each group. (B) H3K27me3 is enriched at the promoter region of Nrf2
region is decreased in NSCLC tissues compared to that in normal tissues. NSCLC tissues an
antibody respectively. Anti-IgG antibody served as a control. N = 8 in each group. (D) Glob
Protein was extracted from NSCLC and normal tissues and subjected to Western blot an
analysis the correlation between H3K27me3 enrichment at Nrf2 promoter and Nrf2 (E)signiﬁcantly correlated with the expression level of Nrf2 and its
downstream genes (Fig. 4E, F and data not shown).
3.4. EZH2 regulates Nrf2 expression through trimethylation of H3K27
To further demonstrate the effect of EZH2 on Nrf2 and its down-
stream genes, we knocked down or overexpressed EZH2 in A549
lung cancer cells. We found that EZH2 knockdown signiﬁcantly
up-regulated the mRNA level of Nrf2 (Fig. 5A), while EZH2 overex-
pression down-regulated the mRNA level of Nrf2 (Fig. 5B). In line
with this ﬁnding, EZH2 knockdown decreased H3K27me3 level
and up-regulated Nrf2 protein level, whereas EZH2 overexpression
increased H3K27me3 level and down-regulated Nrf2 protein level
(Fig. 5C). In addition, EZH2 overexpression enhanced H3K27me3
enrichment at the promoter of Nrf2 (Fig. 5D), indicating that
EZH2 may inhibit Nrf2 promoter activity. Indeed, our luciferase
assay showed that EZH2 overexpression inhibited the activity of
Nrf2 promoter (Fig. 5E). Finally, we analyzed the mRNA level of
Nrf2 downstream genes in A549 cells with EZH2 overexpression.
The results showed that EZH2 overexpression signiﬁcantly down-
regulated the mRNA levels of NQO-1 and HO-1 (Fig. 5F). Those ﬁnd-
ings provide direct evidence that EZH2 inhibits Nrf2 expression by
regulating H3K27me3. As previous report has showed that EZH2
expression was correlated with Nrf1 level when cancer cells were
treated with proteasome inhibitor MG132, we also assessed the
effect of EZH2 on Nrf1 expression. However, our data showed that
neither EZH2 overexpression nor EZH2 knockdown could alter the
mRNA level of Nrf1 in A549 cells (Supplementary Fig. 6).
3.5. Nrf2 is essential for the function of EZH2 in A549 lung cancer cell
proliferation
Our data have demonstrated that EZH2 inhibited Nrf2 expres-
sion through regulating H3K27me3 methylation at Nrf2 promoter.ere subjected to ChIP analysis with anti-EZH2, anti-H3K27me3 or control anti-IgG
control and Actin as negative control. (A) EZH2 can bind to the promoter region of
gene. N = 5 in each group. (C) EZH2 and H3K27me3 enrichment on Nrf2 promoter
d normal tissues were subjected to ChIP analysis with anti-EZH2 or anti-H3K27me3
al H3K27me3 level is decreased in NSCLC tissues compared to that in normal tissues.
alysis with indicated antibodies. (E, F) Linear regression analysis was performed to
or NQO-1 (F) mRNA level.
Fig. 5. EZH2 inhibits Nrf2 expression by targeting H3K27me3. A549 cells were infected with retro-sh-Ctrl, retro-sh-EZH2-1#, Ad-Ctrl or Ad-EZH2 for 48 h, then RNA and
protein were extracted and subjected to q-PCR analysis (A, B, F) or Western blot analysis (C) respectively. (A) EZH2 knockdown increases Nrf2 mRNA level. (B) EZH2
overexpression decreases Nrf2 mRNA level. (C) EZH2 knockdown decreases H3K27me3 level and increases Nrf2 protein level, while ENH2 overexpression increases
H3K27me3 level and decreases Nrf2 protein level. (D) EZH2 overexpression increases H3K27me3 enrichment at Nrf2 promoter. A549 cells were infected with Ad-Ctrl or Ad-
EZH2 for 48 h. Then the samples were subjected to ChIP analysis with indicated antibodies. HoxA10 serves as a positive control and Actin as a negative control. (E) Luciferase
assay showing that EZH2 overexpression decreases Nrf2 promoter activity. (F) EZH2 overexpression decreases NQO-1 and HO-1 mRNA level. ⁄⁄P < 0.01.
Fig. 6. Nrf2 is essential for EZH2 effects on lung cancer cell growth. (A) Nrf2 and EZH2 knockdown in A549 cells. (B) Nrf2-knockdown blocks EZH2’s effects on cell
proliferation. A549 cells stalely expressing sh-Ctrl or sh-Nrf2 were infected with retrovirus carrying sh-Ctrl or sh-EZH2. The relative cell number was evaluated at the
indicated time points. ⁄P < 0.05; ⁄⁄P < 0.01 indicate sh-Ctrl versus sh-EZH2; #P < 0.05; ##P < 0.01 indicate sh-Ctrl versus sh-sh-Nrf2. (C) Nrf2-knockdown blocks EZH2’s effects
on colony formation. A549 cells stably expressing sh-Ctrl or sh-Nrf2 were infected with retrovirus carrying sh-Ctrl or sh-EZH2. Then the cells were subjected to soft sugar
colony formation assay. (D) High Nrf2 level predicts poor survival. Kaplan–Meier curve comparing time to survival between NSCLCs with the low versus high Nrf2 expression
was determined using the q-PCR results.
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the role of EZH2 in lung cancer cells. We generated A549 cells with
stably Nrf2 knockdown (Fig. 6A), then we infected those cells withretrovirus carrying Ctrl shRNA, and EZH2 shRNA. We found that
EZH2 knockdown was unable to affect either A549 cell prolifera-
tion (Fig. 6B) or colony formation capacity (Fig. 6C) when Nrf2
3006 Z. Li et al. / FEBS Letters 588 (2014) 3000–3007was knocked down, whereas modulation of EZH2 could still inhibit
A549 cell proliferation and colony formation when Nrf2 shRNA
was replaced by a control shRNA (Fig. 6B and C). Finally, we
showed that high Nrf2 level predicted poor survival (Fig. 6D).
Those ﬁndings demonstrate that Nrf2 is critically essential for
the role of EZH2 in lung cancer cells.
4. Discussion
EZH2 was ﬁrst reported to participate in the progression of
prostate cancer ten years ago [6]. Ectopic expression of EZH2 in
prostate cells induces transcriptional repression of a speciﬁc cohort
of genes. Gene silencing mediated by EZH2 requires the SET
domain and is attenuated by inhibiting histone deacetylase
activity. Amounts of both EZH2 messenger RNA and EZH2 protein
are increased in metastatic prostate cancer; in addition, clinically
localized prostate cancers that express higher concentrations of
EZH2 show a poorer prognosis [6]. EZH2 is a marker of aggressive
breast cancer and promotes neoplastic transformation of breast
epithelial cells [7]. Mechanistically, EZH2 mediates transcriptional
silencing of the tumor suppressor gene E-cadherin by
trimethylation of H3K27 [24]. EZH2 is essential for the
proliferation of both transformed and non-transformed human
cells [25]. Clinical evidence identiﬁed EZH2 as a novel and
independent prognostic marker in endometrial cancer, and vali-
date previous ﬁndings on prostate and breast cancer [26]. Interest-
ingly, a recent report showed that EZH2 serves as a tumor
suppressor in myelodysplastic syndromes, which was evidenced
by EZH2 deletions, missense and frameshift mutations [27]. Here
we showed the down-regulation of EZH2 in human NSCLC tissues.
We further found that EZH2 serves as a tumor suppressor in lung
cancers.
Nrf2 has long been considered to be a factor against environ-
mental oxidative stress. However, recently evidence have showed
that Nrf2 can promote cancer cell proliferation and regulate drug
resistance. Accumulating data have strongly demonstrated the
oncogenic role of Nrf2 in human NSCLC. Loss of Keap1 or decreased
Keap1 activity in cancer cells induces greater nuclear accumulation
of Nrf2, causing enhanced transcriptional induction of antioxi-
dants, xenobiotic metabolism enzymes, and drug efﬂux pumps
[14–16]. Cancer related mutations in Nrf2 impair its recognition
by Keap1-Cul3 E3 ligase and promote malignancy [28]. Nrf2
enhances cell proliferation and resistance to anticancer drugs in
human lung cancer [11]. In addition, a recent report showed that
gain of Nrf2 function in NSCLCs confers radio-resistance [17]. Our
recent work identiﬁed acetylation affects Nrf2 function in human
lung cancer. We showed that hMOF, the histone acetyltransferase
required for histone H4 lysine 16 acetylation, can bind to Nrf2
and acetylates Nrf2. hMOF-dependent Nrf2 acetylation maintains
its retention in the nucleus and mediates the transactivity of
Nrf2, subsequently regulates lung cancer growth and drug-
resistance [18]. However, the mechanism by which Nrf2 is regu-
lated at the transcription level remains unknown. Herein we
showed that Nrf2 is inhibited by EZH2. The expression of Nrf2
and its downstream genes are correlated with EZH2 expression
and H3K27me3 level in human NSCLC samples. Further, EZH2
could bind to Nrf2 promoter and regulated the trimethylation of
H3K27, which repressed Nrf2 transcription. In lung cancer tissues,
EZH2 down-regulation or mutation leads to the reduction of
H3K27me3 at the promoter of Nrf2, resulting in up-regulation of
Nrf2 transcription. However, translated Nrf2 proteins might be
unable to degenerate timely, as previous report has showed muta-
tions in KEAP1 in approximately 20% of patients and 50% of cell
lines in NSCLC, which leads to Nrf2 phosphorylation/acetylation
and nuclear translocation [14,18]. Together with our previousreport, we identiﬁed the underlying mechanism by which Nrf2 is
regulated at transcriptional and post-translational levels. Finally,
Nrf2 was critically essential for the role of EZH2 in human lung
cancer cells, and high Nrf2 level predicts poor survival.
In summary, low EZH2 expression predicts poor survival in
human NSCLC. Our in vitro and in vivo evidence demonstrate that
EZH2 inhibits lung cancer cell growth. Mechanistically, EZH2 binds
to the promoter of Nrf2 and represses Nrf2 expression by regulat-
ing H3K27me3. Finally, we show that Nrf2 is essential for the role
of EZH2 in lung cancer cells.
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